Orforglipron Clinical Trials (2026): 29 Studies for Overweight & Obesity
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
29 Orforglipron clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 9 indications (including Overweight & Obesity) and 28,548 total planned enrollment. 23 Phase 3 Orforglipron trials are listed. 6 Orforglipron clinical trials are actively recruiting at 91 U.S. sites across 25 states. Most recent activity: NCT07241390 (Aug 2031).
Where to Participate: All Orforglipron Trial Sites in the U.S. (91 sites across 25 states)
Every actively recruiting Orforgliprontrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | University of Alabama -The Kirklin Clinic | Birmingham35233 | NCT07202884 | Map |
| AL | AMR Clinical | Mobile36608 | NCT07202884 | Map |
| AZ | Mercy Gilbert Medical Center | Gilbert85297 | NCT07223593 | Map |
| AZ | Urologic Surgeons of Arizona | Mesa85206 | NCT07202884 | Map |
| AZ | Arizona Research Center | Phoenix85053 | NCT07153471 | Map |
| AZ | Emvera Health at Peak Heart & Vascular Surprise | Surprise85378 | NCT07223593 | Map |
| AZ | AMR Clinical | Tempe85281 | NCT07153471 | Map |
| AZ | Del Sol Research Management, LLC | Tucson85715 | NCT07223593 | Map |
| CA | Care Access - Huntington Beach | Huntington Beach92648 | NCT07153471 | Map |
| CA | Matrix Clinical Research | Los Angeles90057 | NCT07202884 | Map |
| CA | Alarcon Urology Center | Montebello90640 | NCT07202884 | Map |
| CA | Valley Clinical Trials, Inc. | Northridge91325 | NCT07223593 | Map |
| CA | The Cardiovascular Center | Redding96001 | NCT07223593 | Map |
| CA | Care Access - Thousand Oaks | Thousand Oaks91360 | NCT07153471 | Map |
| CA | Prestige Medical Group | Tustin92780 | NCT07202884 | Map |
| CA | InvivoCure | Van Nuys91405 | NCT07223593 | Map |
| CA | Carey Chronis MD Pediatric, Infant and Adolescent Medicine | Ventura93003-5369 | NCT06672939 | Map |
| CA | Interventional Cardiology Medical Group | West Hills91307 | NCT07223593 | Map |
| CO | Legacy Clinical Trials | Colorado Springs80909 | NCT07153471 | Map |
| CO | Colorado Clinical Research | Lakewood80228 | NCT07202884 | Map |
| CT | Stamford Therapeutics Consortium | Stamford06905 | NCT06672939 | Map |
| CT | Chase Medical Research, LLC | Waterbury06708 | NCT07153471 | Map |
| FL | AMR Clinical | Fort Myers33912 | NCT07202884 | Map |
| FL | Altus Research | Lake Worth33461 | NCT07202884 | Map |
| FL | Lakeview Institute of Clinical Research | Leesburg34748 | NCT07223593 | Map |
| FL | New Age Medical Research Corporation | Miami33186 | NCT07202884 | Map |
| FL | Floridian Clinical Research, LLC | Miami Lakes33016-1518 | NCT07223593 | Map |
| FL | Inpatient Research Clinic | Miami Lakes33014 | NCT07223593 | Map |
| FL | Emerald Coast OBGYN Clinical Research | Panama City32405 | NCT07202884 | Map |
| FL | St Johns Center for Clinical Research | Saint Augustine32086 | NCT07223593 | Map |
| GA | Children's Healthcare of Atlanta - Center for Advanced Pediatrics | Atlanta30329 | NCT06672939 | Map |
| GA | Care Access - Decatur | Decatur30030 | NCT07153471 | Map |
| GA | Teak Research Consults | Lawrenceville30043 | NCT07202884 | Map |
| GA | North Georgia Clinical Research | Woodstock30189 | NCT07153471 | Map |
| IL | Ann & Robert H. Lurie Children's Hospital of Chicago | Chicago60611 | NCT06672939 | Map |
| IL | Northwestern University | Chicago60611 | NCT07153471 | Map |
| IN | ASHA Clinical Research - Munster, LLC | Hammond46324 | NCT07223593 | Map |
| IN | Indiana University Health Methodist Hospital | Indianapolis46202 | NCT07223593 | Map |
| IN | Deaconess Clinic- Gateway | Newburgh47630 | NCT07223593 | Map |
| KS | AMR Clinical | Newton67114 | NCT07153471 | Map |
| LA | Velocity Clinical Research | Lafayette70508 | NCT06672939 | Map |
| MD | Flourish Research - Bowie | Bowie20715 | NCT07223593 | Map |
| MA | MedVadis Research Corporation | Waltham02451 | NCT07153471 | Map |
| MI | Arcturus Healthcare , PLC, Troy Internal Medicine Research Division | Troy48098 | NCT07202884 | Map |
| MI | Arcturus Healthcare , PLC, Troy Internal Medicine Research Division | Troy48098 | NCT07223593 | Map |
| MS | MedPharmics, LLC | Gulfport39503-2637 | NCT06672939 | Map |
| MO | StudyMetrix Research | City of Saint Peters63303 | NCT07153471 | Map |
| MO | AMR Clinical | Kansas City64114 | NCT07153471 | Map |
| MO | Sundance Clinical Research | St Louis63141-7068 | NCT06672939 | Map |
| NJ | Cardio Metabolic Institute | Somerset08873 | NCT07153471 | Map |
| NC | Lucas Research, Inc | Morehead City28557 | NCT06672549 | Map |
| NC | Lucas Research, Inc. | Morehead City28557 | NCT06672939 | Map |
| NC | Carolina Research Center | Shelby28150 | NCT07153471 | Map |
| PA | University Orthopedics Center | Altoona16602 | NCT07153471 | Map |
| PA | Capital Area Research, LLC | Camp Hill17011 | NCT07223593 | Map |
| PA | OB/GYN Associates of Erie | Erie16507 | NCT07202884 | Map |
| PA | Clinical Research of Philadelphia | Philadelphia19114 | NCT07202884 | Map |
| PA | Childrens Hospital of Pittsburgh | Pittsburgh15224 | NCT06672939 | Map |
| SD | Care Access - Rapid City | Rapid City57701 | NCT07153471 | Map |
| TN | The Jackson Clinic | Jackson38305 | NCT07223593 | Map |
| TN | East Coast Institute for Research - Jefferson City | Jefferson City37760 | NCT07223593 | Map |
| TN | AMR Clinical | Knoxville37909 | NCT07153471 | Map |
| TN | Vanderbilt Health One Hundred Oaks | Nashville37212 | NCT06672939 | Map |
| TX | Mercy Family Clinic | Dallas75208 | NCT07153471 | Map |
| TX | Biopharma Informatic, LLC | Houston77084 | NCT07153471 | Map |
| TX | Biopharma Informatic, LLC | Houston77084 | NCT07223593 | Map |
| TX | Dynamed Clinical Research, LP d/b/a DM Clinical Research | Houston77065 | NCT06672939 | Map |
| TX | Innovative Medical Research of Texas | Houston77065 | NCT07202884 | Map |
| TX | Juno Research | Houston77040 | NCT07153471 | Map |
| TX | La Providence Pediatrics Clinic - Chemidox Clinical Trials | Houston77071-1008 | NCT06672939 | Map |
| TX | Next Level Urgent Care | Houston77057 | NCT07202884 | Map |
| TX | Research Physicians Network, LLC | Houston77089 | NCT07223593 | Map |
| TX | Activian Clinical Research | Kingwood77339 | NCT07153471 | Map |
| TX | Sherman Clinical Research | Sherman75090 | NCT07223593 | Map |
| TX | Advanced Rheumatology of Houston - Woodlands | The Woodlands77382 | NCT07153471 | Map |
| TX | Martin Diagnostic Clinic | Tomball77375-3332 | NCT06672939 | Map |
| TX | NextStage Clinical Research - Waco | Waco76712 | NCT07223593 | Map |
| UT | Alpine Research Organization | Clinton84015 | NCT07223593 | Map |
| UT | Velocity Clinical Research, Salt Lake City | South Jordan84088 | NCT06672939 | Map |
| VA | Charlottesville Medical Research | Charlottesville22911 | NCT07153471 | Map |
| VA | Stroobants Cardiovascular Center | Lynchburg24501 | NCT07223593 | Map |
| VA | Health Research of Hampton Roads, Inc. | Newport News23606 | NCT07202884 | Map |
| VA | Clinical Research Partners, LLC | Richmond23226 | NCT07223593 | Map |
| VA | Gershon Pain Specialists | Virginia Beach23454 | NCT07153471 | Map |
| VA | Gershon Pain Specialists | Virginia Beach23454 | NCT07223593 | Map |
| VA | Urology of Virginia | Virginia Beach23462 | NCT07202884 | Map |
| WA | Northwest Clinical Research Center | Bellevue98007 | NCT07153471 | Map |
| WA | Northwest Clinical Research Center | Bellevue98007 | NCT07202884 | Map |
| WA | ERA Health Research - CardioNow - Lynnwood | Lynnwood98036 | NCT07223593 | Map |
| WA | Eastside Research Associates | Redmond98052 | NCT07223593 | Map |
| WA | Seattle Clinical Research Center | Seattle98104 | NCT07202884 | Map |
Orforglipron clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | Total |
|---|---|---|---|---|
| P1 | 6 | 6 | ||
| P3 | 6 | 8 | 9 | 23 |
Recruiting Orforglipron clinical trials (6)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07241390 | LY3502970A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) | P3 | Atherosclerosis Cardiovascular Disease | 7,140 | Dec 2025 |
| NCT06672939 | LY3502970A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities | P3 | Obesity | 150 | Nov 2024 |
| NCT07223593 | ATTAIN-PADEfficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease | P3 | Peripheral Arterial Disease | 1,205 | Oct 2025 |
| NCT07153471 | ATTAIN-OA PAINA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee | P3 | Osteoarthritis | 800 | Sep 2025 |
| NCT07202884 | RESTRAIN-SUIA Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight | P3 | Urinary Incontinence,Stress | 1,000 | Sep 2025 |
| NCT06672549 | ADVANCEA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | P3 | Obesity | 125 | Nov 2024 |
Orforglipron clinical trials by indication
Obesity (10)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06672939 | LY3502970 | P3 | recruiting | A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities |
| NCT05869903 | ATTAIN-1 | P3 | active not recruiting | A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities |
| NCT06972472 | LY3502970 | P3 | active not recruiting | A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes |
| NCT06972459 | LY3502970 | P3 | active not recruiting | A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity |
| NCT06993792 | LY3502970 | P3 | active not recruiting | A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes |
| NCT06672549 | ADVANCE | P3 | recruiting | A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) |
| NCT06824051 | LY3502970 | P1 | completed | A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight |
| NCT06584916 | ATTAIN-MAINTAIN | P3 | completed | A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN) |
| + 2 more, see All trials below. | ||||
Type 2 Diabetes (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05803421 | ACHIEVE-4 | P3 | completed | A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk |
| NCT06192108 | ACHIEVE-2 | P3 | completed | A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin |
| NCT06109311 | ACHIEVE-5 | P3 | completed | A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor |
| NCT06045221 | ACHIEVE-3 | P3 | completed | A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin |
| NCT06010004 | ACHIEVE-J | P3 | completed | A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes |
| NCT05971940 | ACHIEVE-1 | P3 | completed | A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone |
Healthy (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06692348 | LY3502970 | P1 | completed | A Study of Orforglipron (LY3502970) to Compare a Single Capsule and Multiple Capsules in Healthy Participants |
| NCT06440980 | LY3502970 | P1 | completed | A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight |
| NCT06704763 | LY3502970 | P1 | completed | A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants |
| NCT06370728 | DDI | P1 | completed | A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants |
| NCT06186622 | LY3502970 | P1 | completed | A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants |
Hypertension (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06948422 | LY3502970 | P3 | active not recruiting | A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) |
| NCT06952530 | LY3502970 | P3 | active not recruiting | A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 |
| NCT06948435 | LY3502970 | P3 | active not recruiting | A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 |
Atherosclerosis Cardiovascular Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07241390 | LY3502970 | P3 | recruiting | A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) |
Peripheral Arterial Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07223593 | ATTAIN-PAD | P3 | recruiting | Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease |
Urinary Incontinence,Stress (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07202884 | RESTRAIN-SUI | P3 | recruiting | A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight |
Osteoarthritis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07153471 | ATTAIN-OA PAIN | P3 | recruiting | A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee |
OSA (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06649045 | ATTAIN-OSA | P3 | active not recruiting | A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight |
Orforglipron pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| LY3502970 | NCT07241390 | P3 | recruiting | Atherosclerosis Cardiovascular Disease | 7,140 | — |
| LY3502970 | NCT06672939 | P3 | recruiting | Obesity | 150 | — |
| ATTAIN-PAD | NCT07223593 | P3 | recruiting | Peripheral Arterial Disease | 1,205 | — |
| ATTAIN-OA PAIN | NCT07153471 | P3 | recruiting | Osteoarthritis | 800 | — |
| RESTRAIN-SUI | NCT07202884 | P3 | recruiting | Urinary Incontinence,Stress | 1,000 | — |
| ATTAIN-1 | NCT05869903 | P3 | active not recruiting | Obesity | 3,127 | — |
| LY3502970 | NCT06948422 | P3 | active not recruiting | Hypertension | 974 | — |
| LY3502970 | NCT06952530 | P3 | active not recruiting | Hypertension | 487 | — |
| LY3502970 | NCT06948435 | P3 | active not recruiting | Hypertension | 487 | — |
| LY3502970 | NCT06972472 | P3 | active not recruiting | Obesity | 600 | — |
| LY3502970 | NCT06972459 | P3 | active not recruiting | Obesity | 600 | — |
| LY3502970 | NCT06993792 | P3 | active not recruiting | Obesity | 1,200 | — |
| ADVANCE | NCT06672549 | P3 | recruiting | Obesity | 125 | — |
| ATTAIN-OSA | NCT06649045 | P3 | active not recruiting | OSA | 600 | — |
| ACHIEVE-4 | NCT05803421 | P3 | completed | Type 2 Diabetes | 2,749 | — |
| ATTAIN-MAINTAIN | NCT06584916 | P3 | completed | Obesity | 376 | — |
| ACHIEVE-2 | NCT06192108 | P3 | completed | Type 2 Diabetes | 962 | — |
| ACHIEVE-5 | NCT06109311 | P3 | completed | Type 2 Diabetes | 546 | — |
| ACHIEVE-3 | NCT06045221 | P3 | completed | Type 2 Diabetes | 1,698 | — |
| ATTAIN-2 | NCT05872620 | P3 | completed | Obesity | 1,613 | — |
| ATTAIN-J | NCT05931380 | P3 | completed | Obesity | 238 | — |
| ACHIEVE-J | NCT06010004 | P3 | completed | Type 2 Diabetes | 466 | — |
| ACHIEVE-1 | NCT05971940 | P3 | completed | Type 2 Diabetes | 559 | — |
All Orforglipron trials (29)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07241390 | LY3502970 | A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) | P3 | recruiting | 7,140 | Eli Lilly and Company | Dec 2025 |
| NCT06672939 | LY3502970 | A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities | P3 | recruiting | 150 | Eli Lilly and Company | Nov 2024 |
| NCT07223593 | ATTAIN-PAD | Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease | P3 | recruiting | 1,205 | Eli Lilly and Company | Oct 2025 |
| NCT07153471 | ATTAIN-OA PAIN | A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee | P3 | recruiting | 800 | Eli Lilly and Company | Sep 2025 |
| NCT07202884 | RESTRAIN-SUI | A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight | P3 | recruiting | 1,000 | Eli Lilly and Company | Sep 2025 |
| NCT05869903 | ATTAIN-1 | A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities | P3 | active not recruiting | 3,127 | Eli Lilly and Company | Jun 2023 |
| NCT06948422 | LY3502970 | A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) | P3 | active not recruiting | 974 | Eli Lilly and Company | Apr 2025 |
| NCT06952530 | LY3502970 | A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 | P3 | active not recruiting | 487 | Eli Lilly and Company | Apr 2025 |
| NCT06948435 | LY3502970 | A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | P3 | active not recruiting | 487 | Eli Lilly and Company | Apr 2025 |
| NCT06972472 | LY3502970 | A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | P3 | active not recruiting | 600 | Eli Lilly and Company | May 2025 |
| NCT06972459 | LY3502970 | A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity | P3 | active not recruiting | 600 | Eli Lilly and Company | May 2025 |
| NCT06993792 | LY3502970 | A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | P3 | active not recruiting | 1,200 | Eli Lilly and Company | May 2025 |
| NCT06672549 | ADVANCE | A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | P3 | recruiting | 125 | Eli Lilly and Company | Nov 2024 |
| NCT06649045 | ATTAIN-OSA | A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight | P3 | active not recruiting | 600 | Eli Lilly and Company | Oct 2024 |
| NCT05803421 | ACHIEVE-4 | A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk | P3 | completed | 2,749 | Eli Lilly and Company | Apr 2023 |
| NCT06824051 | LY3502970 | A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight | P1 | completed | 120 | Eli Lilly and Company | Feb 2025 |
| NCT06584916 | ATTAIN-MAINTAIN | A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN) | P3 | completed | 376 | Eli Lilly and Company | Sep 2024 |
| NCT06192108 | ACHIEVE-2 | A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin | P3 | completed | 962 | Eli Lilly and Company | Jan 2024 |
| NCT06109311 | ACHIEVE-5 | A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor | P3 | completed | 546 | Eli Lilly and Company | Nov 2023 |
| NCT06045221 | ACHIEVE-3 | A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin | P3 | completed | 1,698 | Eli Lilly and Company | Sep 2023 |
| NCT05872620 | ATTAIN-2 | A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes | P3 | completed | 1,613 | Eli Lilly and Company | Jun 2023 |
| NCT05931380 | ATTAIN-J | A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease | P3 | completed | 238 | Eli Lilly and Company | Jul 2023 |
| NCT06692348 | LY3502970 | A Study of Orforglipron (LY3502970) to Compare a Single Capsule and Multiple Capsules in Healthy Participants | P1 | completed | 86 | Eli Lilly and Company | Dec 2024 |
| NCT06010004 | ACHIEVE-J | A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes | P3 | completed | 466 | Eli Lilly and Company | Sep 2023 |
| NCT06440980 | LY3502970 | A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight | P1 | completed | 533 | Eli Lilly and Company | Jun 2024 |
| NCT05971940 | ACHIEVE-1 | A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone | P3 | completed | 559 | Eli Lilly and Company | Aug 2023 |
| NCT06704763 | LY3502970 | A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants | P1 | completed | 27 | Eli Lilly and Company | Dec 2024 |
| NCT06370728 | DDI | A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants | P1 | completed | 30 | Eli Lilly and Company | May 2024 |
| NCT06186622 | LY3502970 | A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants | P1 | completed | 50 | Eli Lilly and Company | Jan 2024 |
Orforglipron clinical trials: frequently asked questions
- How many Orforglipron clinical trials are there?
- 29 Orforglipron clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 6 are actively recruiting participants. 15 are marked completed.
- Are Orforglipron clinical trials recruiting in 2026?
- Yes — 6 Orforglipron trials are actively recruiting in 2026, with 91 U.S. sites across 25 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Orforglipron being studied for?
- Orforglipron is being studied for Overweight, Obesity, Type 2 Diabetes, Healthy, Overweight or Obesity and 9 more. The trials are grouped by indication on this page.
- What phase is Orforglipron in?
- Orforglipron clinical trials span 23 Phase 3, 6 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Orforglipron clinical trials?
- The lead sponsor across the most Orforglipron trials is Eli Lilly and Company. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Orforglipronas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: